AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) SVP Joseph Vittiglio sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $16.75, for a total transaction of $20,937.50. Following the completion of the transaction, the senior vice president now owns 33,504 shares in the company, valued at $561,192. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded up 5.39% during midday trading on Friday, reaching $17.60. 847,077 shares of the company traded hands. AMAG Pharmaceuticals, Inc. has a 12 month low of $16.00 and a 12 month high of $36.83. The stock’s market capitalization is $621.07 million. The company’s 50 day moving average is $18.29 and its 200-day moving average is $20.17.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business had revenue of $158.39 million for the quarter, compared to analysts’ expectations of $158.83 million. During the same period last year, the company earned $1.45 earnings per share. The company’s quarterly revenue was up 24.3% on a year-over-year basis. Equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post ($1.38) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Insider Selling: AMAG Pharmaceuticals, Inc. (AMAG) SVP Sells $20,937.50 in Stock” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2017/09/02/insider-selling-amag-pharmaceuticals-inc-amag-svp-sells-20937-50-in-stock.html.

Several equities analysts have weighed in on the stock. Barclays PLC reiterated a “hold” rating and issued a $25.00 target price on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. TheStreet lowered shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Citigroup Inc. decreased their price objective on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Finally, Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $28.09.

A number of hedge funds and other institutional investors have recently made changes to their positions in AMAG. Teachers Advisors LLC boosted its position in shares of AMAG Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 59,891 shares of the specialty pharmaceutical company’s stock worth $2,084,000 after buying an additional 5,216 shares during the period. Bank of Montreal Can boosted its position in shares of AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock worth $1,500,000 after buying an additional 64,898 shares during the period. Louisiana State Employees Retirement System boosted its position in shares of AMAG Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company’s stock worth $316,000 after buying an additional 200 shares during the period. Strs Ohio boosted its position in shares of AMAG Pharmaceuticals by 31.3% in the first quarter. Strs Ohio now owns 35,200 shares of the specialty pharmaceutical company’s stock worth $793,000 after buying an additional 8,400 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in shares of AMAG Pharmaceuticals by 63.3% in the first quarter. Russell Investments Group Ltd. now owns 575,664 shares of the specialty pharmaceutical company’s stock worth $12,981,000 after buying an additional 223,092 shares during the period.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.